Jaakko Lappalainen, vice president of clinical development for Marinus Pharmaceuticals Inc., told BioWorld Today that early phase II success with ganaxolone against cyclin-dependent kinase-like 5 (CDKL5) seizure disorder should not necessarily have taken anyone by surprise, despite a phase III setback last June with the same treatment in drug-resistant focal onset seizures.